Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,812,057
  • Shares Outstanding, K 74,154
  • Annual Sales, $ 301,030 K
  • Annual Income, $ -361,920 K
  • 60-Month Beta 1.96
  • Price/Sales 31.30
  • Price/Cash Flow N/A
  • Price/Book 6.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.31
  • Number of Estimates 10
  • High Estimate -0.89
  • Low Estimate -3.44
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -98.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
111.09 +20.99%
on 06/03/19
135.70 -0.95%
on 06/19/19
+12.74 (+10.47%)
since 05/17/19
3-Month
111.09 +20.99%
on 06/03/19
135.70 -0.95%
on 06/19/19
+7.94 (+6.28%)
since 03/19/19
52-Week
95.21 +41.17%
on 12/24/18
165.87 -18.97%
on 10/01/18
-9.52 (-6.61%)
since 06/19/18

Most Recent Stories

More News
Sarepta Therapeutics (SRPT) Up 2.9% Since Last Earnings Report: Can It Continue?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SRPT : 134.41 (+1.58%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2019, that were previously approved by the Compensation Committee...

SRPT : 134.41 (+1.58%)
Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up

Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.

SRPT : 134.41 (+1.58%)
BMRN : 85.02 (-0.57%)
CLSN : 1.82 (-3.70%)
FCSC : 2.02 (+1.51%)
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 47.81% and 0.11%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

SRPT : 134.41 (+1.58%)
Sarepta Therapeutics: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Wednesday reported a loss of $76.6 million in its first quarter.

SRPT : 134.41 (+1.58%)
Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the three months ended March 31, 2019.

SRPT : 134.41 (+1.58%)
Sarepta Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Sarepta Therapeutics, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern...

SRPT : 134.41 (+1.58%)
Sarepta Announces Agreement with Nationwide Children's Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy

--Expands pipeline with 6 investigational gene therapy for Limb-girdle muscular dystrophy--

SRPT : 134.41 (+1.58%)
Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2019 financial results after the Nasdaq Global Market closes on Wednesday,...

SRPT : 134.41 (+1.58%)
What's in the Cards for Sarepta (SRPT) This Earnings Season?

Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive first-quarter sales.

SRPT : 134.41 (+1.58%)
HZNP : 24.10 (+2.42%)
INCY : 84.87 (+0.70%)
GILD : 68.26 (+0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade SRPT with:

Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma,...

See More

Key Turning Points

2nd Resistance Point 137.34
1st Resistance Point 135.87
Last Price 134.41
1st Support Level 132.77
2nd Support Level 131.14

See More

52-Week High 165.87
Fibonacci 61.8% 138.88
Last Price 134.41
Fibonacci 50% 130.54
Fibonacci 38.2% 122.20
52-Week Low 95.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar